Drugs / LGW16-03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07385430 | Jun 2026 → Aug 2027 expected | peripheral nerve lesion | Eric R. Henderson | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LGW16-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07385430 ↗ |
| Modality | Diagnostic / imaging agent | “LGW16-03 is a non-biological medical imaging agent classified as a contrast agent, consistent with FDA definitions.” NCT07385430 ↗ |
| Route | Intravenous | “Participants will receive a one-time intravenous infusion of the investigational drug (LGW16-03) prior to their planned surgery.” NCT07385430 ↗ |